Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Voordeel van starten met tocilizumab verdwijnt op lange termijn
jan 2020 | RA